API Holdings (Pharmeasy) Unlisted Shares
PHARMEASY SECURES $216 MILLION FUNDING LED BY MANIPAL GROUP, FACES VALUATION CUT
TNEC 24*7
2 min read
PharmEasy Secures $216M Funding Led by Manipal Group Amid Valuation Decline.
Expert Analysis:
Funding Infusion Led by MEMG: PharmEasy secures Rs 1,804 crore ($216 million) funding led by Ranjan Pai’s MEMG, indicating investor confidence.
Significant Valuation Decline: The valuation experienced a sharp decline of approximately 90%, now standing at $710 million.
Funding Breakdown: Valuation drops sharply from $5.6 billion in 2021; MEMG’s family office leads with Rs 800 crore, backed by Prosus, Temasek, and 360 One Portfolios with Rs 221 crore, Rs 183 crore, and Rs 200 crore, respectively. Also, CDPQ Private Equity, WSSS Investments, Goldman Sachs, and Evolution Debt Capital invested Rs 400 crore collectively.
Debt Settlement Efforts: Efforts are underway to raise Rs 3,500 crore to settle debts incurred from defaulting on Goldman Sachs' loan terms.
Valuation Reduction History: Valuation was previously reduced by 50% by Janus Henderson and further by 21.4 percent to $4.4 billion as of February 2023 by Neuberger Berman.
Investor Trust Amid Challenges:
PharmEasy maintains investor trust, leveraging support for market fortification despite valuation adjustments and debt repayment challenges.
Market Fortification and Growth Goals:
The company aims to overcome hurdles, reinforce its market stance, and drive long-term growth objectives with substantial financial backing.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved